查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957517

2026年全球核醫放射性同位素市場報告

Nuclear Medicine Radioisotopes Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，核醫放射性同位素市場規模顯著成長。預計該市場將從2025年的88.5億美元成長到2026年的95.8億美元，複合年成長率（CAGR）為8.2%。過去幾年的成長主要歸功於Technetium-99m在診斷影像中的廣泛應用、核醫學心臟影像的日益普及、癌症和甲狀腺疾病發病率的上升、醫院核醫學科室的擴建以及放射性同位素療法的早期臨床成功。

預計未來幾年，核醫放射性同位素市場規模將強勁成長。到2030年，該市場規模預計將達到127.5億美元，複合年成長率（CAGR）為7.4%。預測期內的成長要素包括：對個人化癌症治療的需求不斷成長、鎦-177和錒-225療法的應用日益廣泛、PET成像基礎設施的擴建、對迴旋加速器和反應器設施投資的增加，以及新興國家核醫學應用的進步。預測期內的主要趨勢包括：腫瘤治療中診療一體化治療診斷學的日益普及、對PET和SPECT成像技術的需求不斷成長、靶向α射線和BETA核子反應爐發射體的使用日益增多、核醫學在心臟病學和神經病學領域的應用不斷擴展，以及對國內放射性同位素生產的日益重視。

未來幾年，心血管疾病發生率的上升預計將推動核醫放射性同位素市場的擴張。心血管疾病是指影響心臟和血管的多種疾病。心血管疾病病例的增加與久坐的生活方式、不良的飲食習慣、肥胖率的上升以及人口老化密切相關。核醫放射性同位素能夠提供有關心臟功能、血流和組織活力的詳細資訊，對於心血管疾病的診斷、評估和治療至關重要，也是準確診斷和有效治療方案製定的關鍵。例如，根據美國心臟協會（美國非營利組織）於2024年1月發布的數據，預計2024年心血管疾病的年齡調整死亡率將達到每10萬人233.3例，比2023年的224.4例增加4.0%。因此，心血管疾病盛行率的上升正在推動核醫學放射性同位素市場的成長。

核醫放射性同位素市場的主要企業正致力於開發先進解決方案，例如新一代診療治療診斷學藥物，以提升精準成像和標靶治療。新一代診療治療診斷學放射性藥物是高度專業化的放射性藥物，能夠精準靶向體內特定細胞，從而實現疾病的檢測和精準治療。例如，2025年11月，美國研究型大學加州大學（University of California）成立了完全獨立的“核醫學與治療診斷學系”，不再將核子醫學作為放射科的一部分。該系旨在加速先進成像技術和標靶放射性藥物療法的應用，並加強研究、教育和臨床項目，以推進精準醫學發展，促進診療治療診斷學治療領域的創新。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球核醫放射性同位素市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 人工智慧（AI）和自主人工智慧
    • 工業4.0和智慧製造
    • 數位化、雲端運算、巨量資料、網路安全
    • 物聯網、智慧基礎設施、互聯生態系統
  • 主要趨勢
    • 腫瘤治療中診療治療診斷學的廣泛應用
    • 對PET和SPECT成像程序的需求增加
    • 擴大標靶α射線和BETA射線發射放射性核素的使用
    • 核子醫學在心臟病學和神經病學領域的拓展
    • 加強對國內放射性同位素生產的重視

第5章 終端用戶產業市場分析

  • 醫院
  • 診斷中心
  • 專科診所
  • 癌症治療中心
  • 教育和研究機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球核醫放射性同位素市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 核醫放射性同位素的全球市場規模、比較與成長率分析。
  • 全球核醫放射性同位素市場表現：規模與成長，2020-2025年
  • 全球核醫放射性同位素市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按類型
  • Technetium-99m (Tc-99m)、鉈-201 (Tl-201)、碘-123 (I-123)、氟-18、銣-82 (Rb-82)、碘-131 (I-131)、鎦-177 (鎦-2317)、鑠Alpharadin等。
  • 透過使用
  • 腫瘤學、心臟病學、甲狀腺病學、神經病學及其他應用領域
  • 最終用戶
  • 醫院、診斷中心、專科診所、教育和研究機構以及其他最終用戶
  • 按類型細分：Technetium-99m (Tc-99m)
  • Technetium-99m 高锝酸鈉、Technetium-99m MDP（亞甲基二膦酸）、Technetium-99m HMPAO（六甲基丙烯胺肟）
  • 按類型細分：鉈-201 (Tl-201)
  • 氯化鉈（Tl-201），用於心臟顯像的鉈-201
  • 按類型細分：碘-123 (I-123)
  • 碘-123 碘化鈉，碘-123 碘氟烷（DatScan）
  • 按類型細分：氟-18
  • FDG（氟代脫氧葡萄糖）F-18，氟化物-18用於骨骼影像診斷
  • 按類型細分：銣-82 (Rb-82)
  • Rb-82（用於PET（正子斷層掃描）影像），Rb-82（用於心臟影像）
  • 按類型細分：碘-131 (I-131)
  • 碘-131（碘化鈉），碘-131用於治療甲狀腺癌，碘-131用於治療甲狀腺亢進
  • 按類型細分：鎦-177 (Lu-177)
  • 鎦-177-DOTATATE、鎦-177 用於治療前列腺癌
  • 按類型細分：鐳-223 (Ra-223) 和Alpharadin
  • 二氯化鐳-223（佐菲戈）， Alpharadin，用於治療骨轉移
  • 按類型細分：其他類型
  • 用於標靶α療法（TAT）的Ac-225、癌症治療的Ac-225、鎵-68（Ga-68）、銅-64（Cu-64）、釔-90（Y-90）

第10章 區域與國別分析

  • 全球核醫放射性同位素市場：依地區分類，歷史資料及預測（2020-2025年、2025-2030年、2035年）
  • 全球核醫放射性同位素市場：依國家分類，歷史資料及預測，2020-2025年、2025-2030年、2035年

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 核醫放射性同位素市場：競爭格局與市場佔有率，2024年
  • 核子醫學放射性同位素市場：公司估值矩陣
  • 核醫放射性同位素市場：公司概況
    • Cardinal Health Inc.
    • Bayer AG
    • Siemens Healthineers AG
    • GE HealthCare Technologies
    • BWX Technologies Inc.

第37章 其他大型企業和創新企業

  • Mallinckrodt Pharmaceuticals, Bracco Imaging SpA, Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation（ANSTO）Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z oo, Radiomedix Inc.

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年核醫放射性同位素市場：提供新機會的國家
  • 2030年核醫放射性同位素市場：新興細分市場機會
  • 2030年核醫放射性同位素市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH5MNMRE01_G26Q1

Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and investigate various medical conditions. These isotopes emit radiation that can be detected and imaged with specialized equipment or can provide therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes.

The main types of nuclear medicine radioisotopes include technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), among others. Technetium-99m (Tc-99m) is a radioactive isotope widely utilized in nuclear medicine imaging procedures for the diagnosis of various medical conditions. Its uses cover areas such as oncology, cardiology, thyroid, neurology, and more, serving end users including hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

Tariffs have impacted the nuclear medicine radioisotopes market by increasing costs associated with importing radioisotopes, enriched materials, cyclotron components, and shielding equipment. These effects are most pronounced in regions dependent on cross-border isotope supply chains, including North America and parts of Europe. Supply disruptions and higher logistics costs have affected diagnostic and therapeutic segments, particularly short half-life isotopes. However, tariffs have also encouraged domestic isotope production, regional cyclotron investments, and supply chain localization, supporting long-term market resilience.

The nuclear medicine radioisotopes market research report is one of a series of new reports from The Business Research Company that provides nuclear medicine radioisotopes market statistics, including nuclear medicine radioisotopes industry global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.85 billion in 2025 to $9.58 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to widespread use of technetium-99m in diagnostic imaging, growing adoption of nuclear cardiology procedures, increasing prevalence of cancer and thyroid disorders, expansion of hospital-based nuclear medicine departments, early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include rising adoption of theranostics in oncology care, growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine in cardiology and neurology, strengthening focus on domestic radioisotope production.

The rising incidence of cardiovascular diseases is expected to drive the expansion of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases include a variety of conditions that affect the heart and blood vessels. The increase in cardiovascular disease cases is linked to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential for diagnosing, evaluating, and managing cardiovascular diseases by offering detailed information on cardiac function, perfusion, and tissue viability, which are vital for accurate diagnosis and effective treatment planning. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the nuclear medicine radioisotope market.

Major companies in the nuclear medicine radioisotopes market are focusing on developing advanced solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted therapies. Next-generation theranostic radiopharmaceuticals are highly specialized radioactive agents designed to both detect and accurately treat diseases by precisely targeting specific cells within the body. For instance, in November 2025, the University of California, a US-based research university, created a completely independent Department of Nuclear Medicine & Theranostics, rather than maintaining nuclear medicine as part of a broader radiology division. This newly established department aims to accelerate the use of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and encourage innovations in theranostic treatments.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aimed to strengthen its nuclear medicine capabilities, optimize production processes, and broaden its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS, headquartered in Canada, provides advanced radioisotope technology and operates in the field of nuclear medicine radioisotopes.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nuclear Medicine Radioisotopes Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses nuclear medicine radioisotopes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nuclear medicine radioisotopes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nuclear medicine radioisotopes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Technetium-99m (Tc-99m); Thallium-201 (Tl-201); Iodine (I-123); Fluorine-18; Rubidium-82 (Rb-82); Iodine-131 (I-131); Lutetium-177 (Lu-177); Radium-223 (Ra-223) And Alpharadin; Other Types
  • 2) By Application: Oncology; Cardiology; Thyroid; Neurology; Other Applications
  • 3) By End-User: Hospitals; Diagnostic Centers; Specialty Clinics; Education And Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m; Tc-99m MDP (Methylene Diphosphonate); Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201; Thallium-201 for Cardiac Imaging
  • 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide; Iodine-123 Ioflupane (DaTscan)
  • 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18; Fluoride-18 For Bone Imaging
  • 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging; Rb-82 For Cardiac Imaging
  • 6) By Iodine-131 (I-131): I-131 Sodium Iodide; I-131 For Thyroid Cancer Treatment; I-131 For Hyperthyroidism Treatment
  • 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE; Lu-177 For Prostate Cancer Treatment
  • 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo); Alpharadin For Bone Metastasis Treatment
  • 9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT); Ac-225 For Cancer Treatment; Gallium-68 (Ga-68); Copper-64 (Cu-64); Yttrium-90 (Y-90)
  • Companies Mentioned: Cardinal Health Inc.; Bayer AG; Siemens Healthineers AG; GE HealthCare Technologies; BWX Technologies Inc.; Mallinckrodt Pharmaceuticals; Bracco Imaging S.p.A.; Lantheus Holdings Inc.; Curium Pharma; Australian Nuclear Science and Technology Organisation (ANSTO) Health; Eckert & Ziegler Strahlen; NorthStar Medical Radioisotopes; NTP Radioisotopes; Shine Medical Technologies Inc.; Jubilant DraxImage Inc.; Isotopia Molecular Imaging Ltd.; EczacIbasI-Monrol Nuclear Products; International Isotopes Inc.; Polatom Sp. z o.o.; Radiomedix Inc.; Positron Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Nuclear Medicine Radioisotopes Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Nuclear Medicine Radioisotopes Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Nuclear Medicine Radioisotopes Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Nuclear Medicine Radioisotopes Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Theranostics In Oncology Care
    • 4.2.2 Growing Demand For Pet And Spect Imaging Procedures
    • 4.2.3 Increased Use Of Targeted Alpha And Beta Emitters
    • 4.2.4 Expansion Of Nuclear Medicine In Cardiology And Neurology
    • 4.2.5 Strengthening Focus On Domestic Radioisotope Production

5. Nuclear Medicine Radioisotopes Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Diagnostic Centers
  • 5.3 Specialty Clinics
  • 5.4 Cancer Treatment Centers
  • 5.5 Education And Research Institutes

6. Nuclear Medicine Radioisotopes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Nuclear Medicine Radioisotopes Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Nuclear Medicine Radioisotopes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Nuclear Medicine Radioisotopes Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Nuclear Medicine Radioisotopes Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Nuclear Medicine Radioisotopes Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Nuclear Medicine Radioisotopes Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Nuclear Medicine Radioisotopes Market Segmentation

  • 9.1. Global Nuclear Medicine Radioisotopes Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types
  • 9.2. Global Nuclear Medicine Radioisotopes Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiology, Thyroid, Neurology, Other Applications
  • 9.3. Global Nuclear Medicine Radioisotopes Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users
  • 9.4. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Technetium-99m (Tc-99m), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime)
  • 9.5. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Thallium-201 (Tl-201), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Thallous Chloride Tl-201, Thallium-201 For Cardiac Imaging
  • 9.6. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-123 (I-123), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan)
  • 9.7. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Fluorine-18, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging
  • 9.8. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Rubidium-82 (Rb-82), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging
  • 9.9. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Iodine-131 (I-131), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment
  • 9.10. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Lutetium-177 (Lu-177), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment
  • 9.11. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Radium-223 (Ra-223) And Alpharadin, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment
  • 9.12. Global Nuclear Medicine Radioisotopes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

10. Nuclear Medicine Radioisotopes Market Regional And Country Analysis

  • 10.1. Global Nuclear Medicine Radioisotopes Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Nuclear Medicine Radioisotopes Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Nuclear Medicine Radioisotopes Market

  • 11.1. Asia-Pacific Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Nuclear Medicine Radioisotopes Market

  • 12.1. China Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Nuclear Medicine Radioisotopes Market

  • 13.1. India Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Nuclear Medicine Radioisotopes Market

  • 14.1. Japan Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Nuclear Medicine Radioisotopes Market

  • 15.1. Australia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Nuclear Medicine Radioisotopes Market

  • 16.1. Indonesia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Nuclear Medicine Radioisotopes Market

  • 17.1. South Korea Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Nuclear Medicine Radioisotopes Market

  • 18.1. Taiwan Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Nuclear Medicine Radioisotopes Market

  • 19.1. South East Asia Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Nuclear Medicine Radioisotopes Market

  • 20.1. Western Europe Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Nuclear Medicine Radioisotopes Market

  • 21.1. UK Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Nuclear Medicine Radioisotopes Market

  • 22.1. Germany Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Nuclear Medicine Radioisotopes Market

  • 23.1. France Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Nuclear Medicine Radioisotopes Market

  • 24.1. Italy Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Nuclear Medicine Radioisotopes Market

  • 25.1. Spain Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Nuclear Medicine Radioisotopes Market

  • 26.1. Eastern Europe Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Nuclear Medicine Radioisotopes Market

  • 27.1. Russia Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Nuclear Medicine Radioisotopes Market

  • 28.1. North America Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Nuclear Medicine Radioisotopes Market

  • 29.1. USA Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Nuclear Medicine Radioisotopes Market

  • 30.1. Canada Nuclear Medicine Radioisotopes Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Nuclear Medicine Radioisotopes Market

  • 31.1. South America Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Nuclear Medicine Radioisotopes Market

  • 32.1. Brazil Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Nuclear Medicine Radioisotopes Market

  • 33.1. Middle East Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Nuclear Medicine Radioisotopes Market

  • 34.1. Africa Nuclear Medicine Radioisotopes Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Nuclear Medicine Radioisotopes Market, Segmentation By Type, Segmentation By Application, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Nuclear Medicine Radioisotopes Market Regulatory and Investment Landscape

36. Nuclear Medicine Radioisotopes Market Competitive Landscape And Company Profiles

  • 36.1. Nuclear Medicine Radioisotopes Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Nuclear Medicine Radioisotopes Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Nuclear Medicine Radioisotopes Market Company Profiles
    • 36.3.1. Cardinal Health Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. GE HealthCare Technologies Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. BWX Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Nuclear Medicine Radioisotopes Market Other Major And Innovative Companies

  • Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., EczacIbasI-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc.

38. Global Nuclear Medicine Radioisotopes Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market

40. Nuclear Medicine Radioisotopes Market High Potential Countries, Segments and Strategies

  • 40.1 Nuclear Medicine Radioisotopes Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Nuclear Medicine Radioisotopes Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Nuclear Medicine Radioisotopes Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer